[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2008084698A1 - タクロリムス徐放性医薬組成物 - Google Patents

タクロリムス徐放性医薬組成物 Download PDF

Info

Publication number
WO2008084698A1
WO2008084698A1 PCT/JP2007/074999 JP2007074999W WO2008084698A1 WO 2008084698 A1 WO2008084698 A1 WO 2008084698A1 JP 2007074999 W JP2007074999 W JP 2007074999W WO 2008084698 A1 WO2008084698 A1 WO 2008084698A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
sustained release
release pharmaceutical
tacrolimus
tacrolimus sustained
Prior art date
Application number
PCT/JP2007/074999
Other languages
English (en)
French (fr)
Inventor
Hiromu Kondo
Hiroyuki Kojima
Keiichi Yoshihara
Yuko Taketani
Takuya Ishii
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to EP07860228A priority Critical patent/EP2119442A4/en
Priority to CA002674039A priority patent/CA2674039A1/en
Priority to JP2008553066A priority patent/JPWO2008084698A1/ja
Publication of WO2008084698A1 publication Critical patent/WO2008084698A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

　タクロリムス又はその製薬学的に許容される塩を含む固体分散体、及び徐放性医薬組成物用担体を含有し、溶出試験開始４時間後のタクロリムスの溶出率が３５％未満であるタクロリムス徐放性医薬組成物を開示する。
PCT/JP2007/074999 2006-12-28 2007-12-26 タクロリムス徐放性医薬組成物 WO2008084698A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07860228A EP2119442A4 (en) 2006-12-28 2007-12-26 PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
CA002674039A CA2674039A1 (en) 2006-12-28 2007-12-26 Sustained release formulation for tacrolimus
JP2008553066A JPWO2008084698A1 (ja) 2006-12-28 2007-12-26 タクロリムス徐放性医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87735506P 2006-12-28 2006-12-28
US60/877,355 2006-12-28

Publications (1)

Publication Number Publication Date
WO2008084698A1 true WO2008084698A1 (ja) 2008-07-17

Family

ID=39608594

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074999 WO2008084698A1 (ja) 2006-12-28 2007-12-26 タクロリムス徐放性医薬組成物

Country Status (5)

Country Link
US (2) US20090011018A1 (ja)
EP (1) EP2119442A4 (ja)
JP (1) JPWO2008084698A1 (ja)
CA (1) CA2674039A1 (ja)
WO (1) WO2008084698A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038690A1 (ja) * 2008-09-30 2010-04-08 アステラス製薬株式会社 放出制御医薬組成物
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2011122524A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
CN103189054A (zh) * 2010-10-19 2013-07-03 李熙烨 含有他克莫斯有效成分的缓释微丸
JP2014521639A (ja) * 2011-07-26 2014-08-28 ユーハン・コーポレイション 二相の放出制御システムによるプレガバリンを含む徐放錠
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2575769T3 (pl) 2010-02-17 2016-12-30 Stabilizowana kompozycja takrolimusu
CN102670556A (zh) * 2011-03-14 2012-09-19 北京天衡药物研究院 他克莫司渗透泵型控释片
TWI722988B (zh) * 2015-06-05 2021-04-01 瑩碩生技醫藥股份有限公司 緩釋性醫藥組合物及其製備方法
KR102081176B1 (ko) * 2018-06-22 2020-02-25 주식회사 종근당 타크로리무스를 포함하는 서방형 약제학적 제제
US11179334B1 (en) * 2019-02-04 2021-11-23 Florida A&M University Targeted carriers for tacrolimus for ocular inflammation
GR1009790B (el) * 2019-03-20 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Σκευασμα παρατεταμενης αποδεσμευσης που περιλαμβανει τακρολιμους
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent

Citations (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133132A (en) 1960-11-29 1964-05-12 Univ California High flow porous membranes for separating water from saline solutions
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4088864A (en) 1974-11-18 1978-05-09 Alza Corporation Process for forming outlet passageways in pills using a laser
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
JPS62277321A (ja) 1986-04-02 1987-12-02 Fujisawa Pharmaceut Co Ltd Ｆｒ―９００５０６物質の固形医薬製剤用固溶体組成物
US4839177A (en) 1985-12-20 1989-06-13 Jagotec Ag System for the controlled-rate release of active substances
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5128143A (en) 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
WO1993016686A1 (en) 1992-02-29 1993-09-02 The Upjohn Company Pharmaceutical preparation for sustained release of a drug and process for producing the same
JPH06172162A (ja) * 1989-12-14 1994-06-21 Jagotec Ag 活性物質の制御された速度の放出を備えた錠剤
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5780057A (en) 1996-02-19 1998-07-14 Jagotec Ag Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
WO1998040051A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
JP2832248B2 (ja) 1993-11-12 1998-12-09 ペンウエスト ファーマシューティカルズ カンパニー メトプロロールまたはメトプロロール塩の徐放性調剤とその製造方法
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO1999044642A1 (en) 1998-03-05 1999-09-10 Phares Pharmaceutical Research Nv Pharmaceutical compositions and their use
WO1999049863A1 (fr) 1998-03-26 1999-10-07 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6149940A (en) 1996-08-29 2000-11-21 Synthelabo Tablet with controlled release of alfuzosine chlorhydrate
US6340475B2 (en) 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO2003013566A1 (en) 2001-08-03 2003-02-20 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
WO2003043603A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
WO2003049753A1 (en) 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
WO2003077827A1 (fr) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Procede de production de medicament solide en dispersion
WO2004000279A1 (fr) 2002-06-25 2003-12-31 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procédé de préparation
WO2004009061A2 (en) 2002-07-18 2004-01-29 Council Of Scientific And Industrial Research Bioavailability/bioefficacy enhaning activity of cuminum cyminum and extracts and fractions thereof
WO2004009075A1 (en) 2002-07-20 2004-01-29 Korea Institute Of Science And Technology Composition for solubilization of paclitaxel and preparation method thereof
WO2004062643A1 (en) 2003-01-14 2004-07-29 Lifecycle Pharma A/S Dry dispersions
WO2004067018A1 (en) 2003-01-30 2004-08-12 Council Of Scientific And Industrial Research Bioavailability enhancing activity of carum carvi extracts and fractions thereof
WO2004071494A2 (en) 2003-02-13 2004-08-26 Phares Pharmaceutical Research N.V. Lipophilic compositions
WO2004087052A2 (en) 2003-03-25 2004-10-14 Lipocine, Inc. Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
WO2005030169A1 (en) 2003-10-02 2005-04-07 Sembiosys Genetics Inc. Methods for preparing oil bodies comprising active ingredients
JP2005162736A (ja) 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
JP2005162737A (ja) 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
PT1663216E (pt) * 2003-08-29 2012-02-14 Veloxis Pharmaceuticals As Dispersões sólidas que compreendem tacrolímus
WO2005032525A1 (en) * 2003-10-03 2005-04-14 Lifecycle Pharma A/S A method for preparing modified release pharmaceutical compositions
US8128958B2 (en) * 2003-11-10 2012-03-06 Astellas Pharma Inc. Sustained release pharmaceutical composition
US8197846B2 (en) * 2003-11-10 2012-06-12 Astellas Pharma Inc. Sustained release pharmaceutical composition

Patent Citations (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3133132A (en) 1960-11-29 1964-05-12 Univ California High flow porous membranes for separating water from saline solutions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4088864A (en) 1974-11-18 1978-05-09 Alza Corporation Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4160020A (en) 1975-11-24 1979-07-03 Alza Corporation Therapeutic device for osmotically dosing at controlled rate
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4839177A (en) 1985-12-20 1989-06-13 Jagotec Ag System for the controlled-rate release of active substances
JPS62277321A (ja) 1986-04-02 1987-12-02 Fujisawa Pharmaceut Co Ltd Ｆｒ―９００５０６物質の固形医薬製剤用固溶体組成物
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
JPH04501713A (ja) * 1988-09-19 1992-03-26 エドワード　メンデル　カンパニー，インコーポレイティド 直接圧縮できる持効性賦形剤
US5128143A (en) 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
JPH06172162A (ja) * 1989-12-14 1994-06-21 Jagotec Ag 活性物質の制御された速度の放出を備えた錠剤
US5422123A (en) 1989-12-14 1995-06-06 Jagotec Ag Tablets with controlled-rate release of active substances
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
WO1993016686A1 (en) 1992-02-29 1993-09-02 The Upjohn Company Pharmaceutical preparation for sustained release of a drug and process for producing the same
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
JP2832248B2 (ja) 1993-11-12 1998-12-09 ペンウエスト ファーマシューティカルズ カンパニー メトプロロールまたはメトプロロール塩の徐放性調剤とその製造方法
US5780057A (en) 1996-02-19 1998-07-14 Jagotec Ag Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
US6149940A (en) 1996-08-29 2000-11-21 Synthelabo Tablet with controlled release of alfuzosine chlorhydrate
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
WO1998040051A1 (en) 1997-03-12 1998-09-17 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
US6340475B2 (en) 1997-06-06 2002-01-22 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1999000113A1 (en) 1997-06-27 1999-01-07 Vivorx Pharmaceuticals, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO1999044642A1 (en) 1998-03-05 1999-09-10 Phares Pharmaceutical Research Nv Pharmaceutical compositions and their use
WO1999049863A1 (fr) 1998-03-26 1999-10-07 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
WO2003013566A1 (en) 2001-08-03 2003-02-20 Shaklee Corporation High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
WO2003043603A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
WO2003049753A1 (en) 2001-12-13 2003-06-19 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
WO2003077827A1 (fr) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Procede de production de medicament solide en dispersion
WO2004000279A1 (fr) 2002-06-25 2003-12-31 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procédé de préparation
WO2004009061A2 (en) 2002-07-18 2004-01-29 Council Of Scientific And Industrial Research Bioavailability/bioefficacy enhaning activity of cuminum cyminum and extracts and fractions thereof
WO2004009075A1 (en) 2002-07-20 2004-01-29 Korea Institute Of Science And Technology Composition for solubilization of paclitaxel and preparation method thereof
WO2004062643A1 (en) 2003-01-14 2004-07-29 Lifecycle Pharma A/S Dry dispersions
WO2004067018A1 (en) 2003-01-30 2004-08-12 Council Of Scientific And Industrial Research Bioavailability enhancing activity of carum carvi extracts and fractions thereof
WO2004071494A2 (en) 2003-02-13 2004-08-26 Phares Pharmaceutical Research N.V. Lipophilic compositions
WO2004087052A2 (en) 2003-03-25 2004-10-14 Lipocine, Inc. Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
WO2005030169A1 (en) 2003-10-02 2005-04-07 Sembiosys Genetics Inc. Methods for preparing oil bodies comprising active ingredients
JP2005162736A (ja) 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
JP2005162737A (ja) 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Encyclopedia of Polymer Science and Technology", vol. 3, 1964, INTERSCIENCE PUBLISHERSINC., pages: 325 - 354
BR.J.CLIN.PHARMAC., vol. 26, 1988, pages 435 - 443
SANTUS; BAKER: "Osmotic drug delivery: a review of the patent literature", JOURNAL OF CONTROLLED RELEASE, vol. 35, 1995, pages 1 - 21, XP004037488, DOI: doi:10.1016/0168-3659(95)00013-X
SCOTT; ROFF: "Handbook of Common Polymers", 1971, CRC PRESS
SCOTT; ROFF: "Handbook of Common Polymers", CHEMICAL RUBBER CO.
See also references of EP2119442A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2345410B1 (en) 2008-09-30 2020-12-30 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2010038690A1 (ja) * 2008-09-30 2010-04-08 アステラス製薬株式会社 放出制御医薬組成物
US12059409B1 (en) 2008-09-30 2024-08-13 Astellas Pharma Inc. Pharmaceutical composition for modified release
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2011122524A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
JPWO2011122523A1 (ja) * 2010-03-29 2013-07-08 アステラス製薬株式会社 放出制御医薬組成物
JPWO2011122524A1 (ja) * 2010-03-29 2013-07-08 アステラス製薬株式会社 放出制御医薬組成物
US8877214B2 (en) 2010-03-29 2014-11-04 Astellas Pharma Inc. Pharmaceutical composition for modified release
JP5849947B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
JP5849946B2 (ja) * 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
US11707451B2 (en) 2010-03-29 2023-07-25 Astellas Pharma Inc. Pharmaceutical composition for modified release
CN103189054A (zh) * 2010-10-19 2013-07-03 李熙烨 含有他克莫斯有效成分的缓释微丸
CN103189054B (zh) * 2010-10-19 2016-06-01 李熙烨 含有他克莫斯有效成分的缓释微丸
JP2014521639A (ja) * 2011-07-26 2014-08-28 ユーハン・コーポレイション 二相の放出制御システムによるプレガバリンを含む徐放錠
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Also Published As

Publication number Publication date
US20110281906A1 (en) 2011-11-17
US20090011018A1 (en) 2009-01-08
EP2119442A1 (en) 2009-11-18
JPWO2008084698A1 (ja) 2010-04-30
EP2119442A4 (en) 2010-12-15
CA2674039A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
WO2008084698A1 (ja) タクロリムス徐放性医薬組成物
WO2006084164A3 (en) Gastric retention and controlled release delivery system
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2007146248A3 (en) Stable laquinimod preparations
WO2007135461A3 (en) Pharmaceutical compositions comprising implitapide and methods of using same
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
WO2006023627A8 (en) Rapamycin polymorph ii and uses thereof
WO2007135193A3 (fr) Forme pharmaceutique orale multimicroparticulaire a liberation prolongee comprenant des moyens anti-mesusage et resistant a l'alcool
HK1123789A1 (en) Azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
WO2006058059A3 (en) Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject
IL193772A0 (en) 4-oxoquinoline derivatives,methods for the preparation thereof and pharmaceutical compositions containing the same
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2006127941A3 (en) Amorphous cinacalcet hydrochloride and preparation thereof
IL196426A0 (en) Microparticulates based on an amphiphilic copolymer, processes for the preparation thereof and pharmaceutical compositions containing the same
WO2007144169A3 (en) Entacapone-derivatives
WO2008006795A3 (en) Indole compounds
WO2008103847A3 (en) Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
IL191758A0 (en) Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof
WO2005112633A3 (en) Compounds and compositions for delivering active agents
IL181022A0 (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same
AU2007204311A8 (en) 6-phenyl-1H-imidazo[4, 5-c]pyridine-4-carbonitrile derivatives as cathepsin K and S inhibitors
EP1935417A4 (en) COMPOSITION FOR USE IN PREVENTING A HYPOGLYCEMIC STATE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860228

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008553066

Country of ref document: JP

Ref document number: 2674039

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007860228

Country of ref document: EP